FDA Authorizes Abbott Libre Duo 10 Day
Analysis based on 25 articles · First reported Aug 25, 2026 · Last updated Aug 28, 2026
The FDA authorization strengthens Abbott's leadership in diabetes technology, potentially boosting sales of its Libre portfolio and expanding its total addressable market. Competitors in the continuous glucose monitoring and insulin pump space may face increased pressure to innovate, while the approval could accelerate adoption of continuous ketone monitoring as a new standard of care.
The U.S. United States — Food and Drug Administration (FDA) authorized Abbott Laboratories' Libre Duo 10 Day system, the world's first dual glucose-ketone sensing biowearable for people with diabetes. The device continuously monitors both glucose and ketone levels, alerting users to rising ketones that could lead to diabetic ketoacidosis (DKA), a serious complication. It received De Novo authorization after a breakthrough device designation, and is the first to meet the FDA's integrated continuous glucose monitoring (iCGM) and integrated continuous glucose and ketone monitoring (iCGK) standards. Abbott plans to launch the device in the U.S. later this year. The system integrates with Abbott's Libre digital health ecosystem and is designed for compatibility with automated insulin delivery systems from Beta Bionics, Insulet, Medtronic (MiniMed), Sequel Med Tech, and Tandem Diabetes Care. Abbott also recently partnered with Alphabet Inc. — Google Health to bring glucose monitoring and AI-driven guidance to the Alphabet Inc. — Google Health app.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard